NO320022B1 - Kontrollert frigjorende farmasoytisk preparat med tilidinmesylat som virkestoff - Google Patents

Kontrollert frigjorende farmasoytisk preparat med tilidinmesylat som virkestoff Download PDF

Info

Publication number: NO320022B1
Authority: NO; Norway
Prior art keywords: tilidine; controlled release; pharmaceutical preparation; oral administration; active ingredient
Prior art date: 1998-12-23

Application number

NO20013060A

Other languages

English (en)

Norwegian (no)

Other versions

NO20013060L (no

NO20013060D0 (no

Inventor

Richard Hirsch

Martin Wesseling

Thomas Struengmann

Original Assignee

Hexal Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-23

Filing date

2001-06-20

Publication date

2005-10-10

2001-06-20 Application filed by Hexal Ag filed Critical Hexal Ag

2001-06-20 Publication of NO20013060L publication Critical patent/NO20013060L/no

2001-06-20 Publication of NO20013060D0 publication Critical patent/NO20013060D0/no

2005-10-10 Publication of NO320022B1 publication Critical patent/NO320022B1/no

Links

229960001402 tilidine Drugs 0.000 title claims abstract description 65
WDEFBBTXULIOBB-WBVHZDCISA-N dextilidine Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)OCC)CCC=C[C@H]1N(C)C WDEFBBTXULIOBB-WBVHZDCISA-N 0.000 title claims abstract description 62
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 title claims abstract description 48
238000013270 controlled release Methods 0.000 title claims description 30
239000000825 pharmaceutical preparation Substances 0.000 title claims description 12
239000013543 active substance Substances 0.000 title 1
239000004480 active ingredient Substances 0.000 claims abstract description 26
239000007787 solid Substances 0.000 claims abstract description 16
239000011159 matrix material Substances 0.000 claims description 30
239000008187 granular material Substances 0.000 claims description 26
239000003826 tablet Substances 0.000 claims description 20
-1 carboxymethylene Chemical group 0.000 claims description 18
239000000654 additive Substances 0.000 claims description 16
239000002775 capsule Substances 0.000 claims description 9
239000000843 powder Substances 0.000 claims description 9
239000008188 pellet Substances 0.000 claims description 8
150000003839 salts Chemical class 0.000 claims description 8
239000000126 substance Substances 0.000 claims description 8
UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims description 7
229960004127 naloxone Drugs 0.000 claims description 7
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 7
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 7
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 7
DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims description 6
239000011230 binding agent Substances 0.000 claims description 6
235000010443 alginic acid Nutrition 0.000 claims description 5
229920000615 alginic acid Polymers 0.000 claims description 5
235000014113 dietary fatty acids Nutrition 0.000 claims description 5
WDEFBBTXULIOBB-UHFFFAOYSA-N ethyl 2-(dimethylamino)-1-phenylcyclohex-3-ene-1-carboxylate Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCC=CC1N(C)C WDEFBBTXULIOBB-UHFFFAOYSA-N 0.000 claims description 5
239000000194 fatty acid Substances 0.000 claims description 5
229930195729 fatty acid Natural products 0.000 claims description 5
150000004665 fatty acids Chemical class 0.000 claims description 5
238000005469 granulation Methods 0.000 claims description 5
230000003179 granulation Effects 0.000 claims description 5
229920001515 polyalkylene glycol Polymers 0.000 claims description 5
150000002191 fatty alcohols Chemical class 0.000 claims description 4
239000000314 lubricant Substances 0.000 claims description 4
239000000463 material Substances 0.000 claims description 4
229920000915 polyvinyl chloride Polymers 0.000 claims description 4
239000004800 polyvinyl chloride Substances 0.000 claims description 4
229920001100 Polydextrose Polymers 0.000 claims description 3
239000003085 diluting agent Substances 0.000 claims description 3
229920001477 hydrophilic polymer Polymers 0.000 claims description 3
229920001600 hydrophobic polymer Polymers 0.000 claims description 3
235000013856 polydextrose Nutrition 0.000 claims description 3
239000001259 polydextrose Substances 0.000 claims description 3
229940035035 polydextrose Drugs 0.000 claims description 3
239000001993 wax Substances 0.000 claims description 3
239000004677 Nylon Substances 0.000 claims description 2
229920002472 Starch Polymers 0.000 claims description 2
239000000783 alginic acid Substances 0.000 claims description 2
229960001126 alginic acid Drugs 0.000 claims description 2
150000004781 alginic acids Chemical class 0.000 claims description 2
239000003963 antioxidant agent Substances 0.000 claims description 2
239000002981 blocking agent Substances 0.000 claims description 2
239000000872 buffer Substances 0.000 claims description 2
229920002678 cellulose Polymers 0.000 claims description 2
229920003086 cellulose ether Polymers 0.000 claims description 2
239000012459 cleaning agent Substances 0.000 claims description 2
239000003086 colorant Substances 0.000 claims description 2
239000002270 dispersing agent Substances 0.000 claims description 2
239000003995 emulsifying agent Substances 0.000 claims description 2
239000000945 filler Substances 0.000 claims description 2
239000000796 flavoring agent Substances 0.000 claims description 2
235000013355 food flavoring agent Nutrition 0.000 claims description 2
150000002314 glycerols Chemical class 0.000 claims description 2
229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
239000002480 mineral oil Substances 0.000 claims description 2
229920001778 nylon Polymers 0.000 claims description 2
239000004014 plasticizer Substances 0.000 claims description 2
229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
239000003755 preservative agent Substances 0.000 claims description 2
108090000623 proteins and genes Proteins 0.000 claims description 2
102000004169 proteins and genes Human genes 0.000 claims description 2
230000000979 retarding effect Effects 0.000 claims description 2
239000008107 starch Substances 0.000 claims description 2
235000019698 starch Nutrition 0.000 claims description 2
239000007885 tablet disintegrant Substances 0.000 claims description 2
235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
239000008158 vegetable oil Substances 0.000 claims description 2
239000000080 wetting agent Substances 0.000 claims description 2
229920000178 Acrylic resin Polymers 0.000 claims 1
239000004925 Acrylic resin Substances 0.000 claims 1
229920000219 Ethylene vinyl alcohol Polymers 0.000 claims 1
239000003795 chemical substances by application Substances 0.000 claims 1
229920001971 elastomer Polymers 0.000 claims 1
239000004715 ethylene vinyl alcohol Substances 0.000 claims 1
RZXDTJIXPSCHCI-UHFFFAOYSA-N hexa-1,5-diene-2,5-diol Chemical compound OC(=C)CCC(O)=C RZXDTJIXPSCHCI-UHFFFAOYSA-N 0.000 claims 1
235000010755 mineral Nutrition 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
238000013268 sustained release Methods 0.000 abstract 1
239000012730 sustained-release form Substances 0.000 abstract 1
238000002360 preparation method Methods 0.000 description 20
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
239000000203 mixture Substances 0.000 description 12
230000037058 blood plasma level Effects 0.000 description 8
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
MUWDJVKYGSDUSH-KALLACGZSA-N ethyl (1s,2r)-2-(dimethylamino)-1-phenylcyclohex-3-ene-1-carboxylate;hydron;chloride Chemical compound Cl.C=1C=CC=CC=1[C@@]1(C(=O)OCC)CCC=C[C@H]1N(C)C MUWDJVKYGSDUSH-KALLACGZSA-N 0.000 description 6
235000019359 magnesium stearate Nutrition 0.000 description 6
229960001502 tilidine hydrochloride Drugs 0.000 description 6
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 5
208000002193 Pain Diseases 0.000 description 5
229920001577 copolymer Polymers 0.000 description 5
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 5
239000001863 hydroxypropyl cellulose Substances 0.000 description 5
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
238000002156 mixing Methods 0.000 description 5
OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 5
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
239000001856 Ethyl cellulose Substances 0.000 description 4
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 4
IRHTZOCLLONTOC-UHFFFAOYSA-N Hexacosan-1-ol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCO IRHTZOCLLONTOC-UHFFFAOYSA-N 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical class COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 4
229920001249 ethyl cellulose Polymers 0.000 description 4
235000019325 ethyl cellulose Nutrition 0.000 description 4
UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical group CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 4
229930195733 hydrocarbon Natural products 0.000 description 4
150000002430 hydrocarbons Chemical class 0.000 description 4
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
239000008101 lactose Substances 0.000 description 4
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
239000000454 talc Substances 0.000 description 4
229910052623 talc Inorganic materials 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 3
239000004354 Hydroxyethyl cellulose Substances 0.000 description 3
229920013820 alkyl cellulose Polymers 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000011248 coating agent Substances 0.000 description 3
238000000576 coating method Methods 0.000 description 3
239000012530 fluid Substances 0.000 description 3
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 3
238000002844 melting Methods 0.000 description 3
230000008018 melting Effects 0.000 description 3
238000005550 wet granulation Methods 0.000 description 3
PDJZPNKVLDWEKI-GOEBONIOSA-N (1R,2S)-nortilidine Chemical compound C=1C=CC=CC=1[C@]1(C(=O)OCC)CCC=C[C@@H]1NC PDJZPNKVLDWEKI-GOEBONIOSA-N 0.000 description 2
HLZKNKRTKFSKGZ-UHFFFAOYSA-N 1-Tetradecanol Natural products CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
229920002125 Sokalan® Polymers 0.000 description 2
RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
229920003144 amino alkyl methacrylate copolymer Polymers 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
239000004359 castor oil Substances 0.000 description 2
235000019438 castor oil Nutrition 0.000 description 2
125000003901 ceryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
229940082500 cetostearyl alcohol Drugs 0.000 description 2
229960000541 cetyl alcohol Drugs 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000001035 drying Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 2
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
229920003063 hydroxymethyl cellulose Polymers 0.000 description 2
229940031574 hydroxymethyl cellulose Drugs 0.000 description 2
239000002207 metabolite Substances 0.000 description 2
238000000034 method Methods 0.000 description 2
229960005181 morphine Drugs 0.000 description 2
125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
GLDOVTGHNKAZLK-UHFFFAOYSA-N n-octadecyl alcohol Natural products CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
125000001997 phenyl group Polymers [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
229920001296 polysiloxane Polymers 0.000 description 2
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
XRSKRSVTUVLURN-UHFFFAOYSA-N 1,3-benzodioxol-4-ol Chemical class OC1=CC=CC2=C1OCO2 XRSKRSVTUVLURN-UHFFFAOYSA-N 0.000 description 1
RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
WCOXQTXVACYMLM-UHFFFAOYSA-N 2,3-bis(12-hydroxyoctadecanoyloxy)propyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC(O)CCCCCC)COC(=O)CCCCCCCCCCC(O)CCCCCC WCOXQTXVACYMLM-UHFFFAOYSA-N 0.000 description 1
HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
VKNASXZDGZNEDA-UHFFFAOYSA-N 2-cyanoethyl 2-methylprop-2-enoate Chemical class CC(=C)C(=O)OCCC#N VKNASXZDGZNEDA-UHFFFAOYSA-N 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
206010000090 Abdominal rigidity Diseases 0.000 description 1
229920002126 Acrylic acid copolymer Polymers 0.000 description 1
229910002012 Aerosil® Inorganic materials 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
208000000094 Chronic Pain Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
206010012335 Dependence Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108010092674 Enkephalins Proteins 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
229920003134 Eudragit® polymer Polymers 0.000 description 1
GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
244000043261 Hevea brasiliensis Species 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
239000005639 Lauric acid Substances 0.000 description 1
URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010029240 Neuritis Diseases 0.000 description 1
102000003840 Opioid Receptors Human genes 0.000 description 1
108090000137 Opioid Receptors Proteins 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
206010065016 Post-traumatic pain Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
208000005298 acute pain Diseases 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
238000004378 air conditioning Methods 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
239000003513 alkali Substances 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000010385 ascorbyl palmitate Nutrition 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
150000004951 benzene Polymers 0.000 description 1
150000001555 benzenes Polymers 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
235000010290 biphenyl Nutrition 0.000 description 1
239000004305 biphenyl Substances 0.000 description 1
BTKAMSWFNMGLGM-DZGCQCFKSA-N bisnortilidine Chemical compound C=1C=CC=CC=1[C@]1(C(=O)OCC)CCC=C[C@@H]1N BTKAMSWFNMGLGM-DZGCQCFKSA-N 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
239000004203 carnauba wax Substances 0.000 description 1
235000013869 carnauba wax Nutrition 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
HNEGQIOMVPPMNR-IHWYPQMZSA-N citraconic acid Chemical compound OC(=O)C(/C)=C\C(O)=O HNEGQIOMVPPMNR-IHWYPQMZSA-N 0.000 description 1
229940018557 citraconic acid Drugs 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000001816 cooling Methods 0.000 description 1
230000007797 corrosion Effects 0.000 description 1
238000005260 corrosion Methods 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
229960002069 diamorphine Drugs 0.000 description 1
150000005682 diethyl carbonates Chemical class 0.000 description 1
235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 description 1
GRWZHXKQBITJKP-UHFFFAOYSA-N dithionous acid Chemical class OS(=O)S(O)=O GRWZHXKQBITJKP-UHFFFAOYSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
235000013399 edible fruits Nutrition 0.000 description 1
238000010828 elution Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
239000005038 ethylene vinyl acetate Substances 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
230000010224 hepatic metabolism Effects 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
229920003145 methacrylic acid copolymer Polymers 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
229920003052 natural elastomer Polymers 0.000 description 1
229920001194 natural rubber Polymers 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
208000004296 neuralgia Diseases 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000003040 nociceptive effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003401 opiate antagonist Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
238000010422 painting Methods 0.000 description 1
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
230000037361 pathway Effects 0.000 description 1
238000005453 pelletization Methods 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
150000003016 phosphoric acids Chemical class 0.000 description 1
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
239000004584 polyacrylic acid Substances 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000193 polymethacrylate Polymers 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
238000003825 pressing Methods 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000008439 repair process Effects 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
239000004289 sodium hydrogen sulphite Substances 0.000 description 1
235000010265 sodium sulphite Nutrition 0.000 description 1
238000007711 solidification Methods 0.000 description 1
230000008023 solidification Effects 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
235000010269 sulphur dioxide Nutrition 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
210000000115 thoracic cavity Anatomy 0.000 description 1
AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
229960000984 tocofersolan Drugs 0.000 description 1
235000010384 tocopherol Nutrition 0.000 description 1
229960001295 tocopherol Drugs 0.000 description 1
229930003799 tocopherol Natural products 0.000 description 1
239000011732 tocopherol Substances 0.000 description 1
229940042585 tocopherol acetate Drugs 0.000 description 1
230000008733 trauma Effects 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
239000002966 varnish Substances 0.000 description 1
229920003176 water-insoluble polymer Polymers 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Steroid Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20013060A 1998-12-23 2001-06-20 Kontrollert frigjorende farmasoytisk preparat med tilidinmesylat som virkestoff NO320022B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19859636A DE19859636A1 (de)	1998-12-23	1998-12-23	Kontrolliert freisetzende pharmazeutische Zusammensetzung mit Tilidinmesylat als Wirkstoff
PCT/EP1999/010381 WO2000038656A1 (de)	1998-12-23	1999-12-23	Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff

Publications (3)

Publication Number	Publication Date
NO20013060L NO20013060L (no)	2001-06-20
NO20013060D0 NO20013060D0 (no)	2001-06-20
NO320022B1 true NO320022B1 (no)	2005-10-10

Family

ID=7892368

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20013060A NO320022B1 (no)	1998-12-23	2001-06-20	Kontrollert frigjorende farmasoytisk preparat med tilidinmesylat som virkestoff

Country Status (21)

Country	Link
US (1)	US6579536B1 (cs)
EP (1)	EP1140031B1 (cs)
JP (1)	JP2002533381A (cs)
AT (1)	ATE252377T1 (cs)
AU (1)	AU770293B2 (cs)
BR (1)	BR9916575A (cs)
CA (1)	CA2355891A1 (cs)
CZ (1)	CZ301628B6 (cs)
DE (2)	DE19859636A1 (cs)
DK (1)	DK1140031T3 (cs)
ES (1)	ES2207334T3 (cs)
HU (1)	HUP0104647A3 (cs)
MX (1)	MXPA01006493A (cs)
NO (1)	NO320022B1 (cs)
NZ (1)	NZ512079A (cs)
PL (1)	PL199024B1 (cs)
PT (1)	PT1140031E (cs)
SK (1)	SK284901B6 (cs)
TR (1)	TR200101864T2 (cs)
WO (1)	WO2000038656A1 (cs)
ZA (1)	ZA200105040B (cs)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2001526228A (ja)	1997-12-22	2001-12-18	ユーロ−セルティーク，エス．エイ．	オピオイド作動薬／拮抗薬の併用
US6375957B1 (en)	1997-12-22	2002-04-23	Euro-Celtique, S.A.	Opioid agonist/opioid antagonist/acetaminophen combinations
EP1935421A1 (en) *	2000-02-08	2008-06-25	Euro-Celtique S.A.	Controlled-release compositions containing opioid agonist and antagonist
HU229705B1 (en)	2000-02-08	2014-05-28	Euro Celtique Sa	Tamper-resistant oral opioid agonist formulations
CN1525851A (zh)	2001-05-11	2004-09-01	��ҩ��޹�˾	抗滥用阿片样物质控释剂型
EP1492505B1 (en)	2002-04-05	2015-06-03	Euro-Celtique S.A.	Pharmaceutical preparation containing oxycodone and naloxone
JP4563642B2 (ja) *	2002-05-31	2010-10-13	ワトソンラボラトリーズ、インコーポレイテッド	医薬製剤
DE10233108A1 (de) *	2002-07-20	2004-01-29	Krewel Meuselbach Gmbh	Retardiertes Schmerzmittel enthaltend Tilidin und ein Lichtschutzmittel
DE10250081A1 (de) *	2002-10-25	2004-05-13	Boehringer Ingelheim Vetmedica Gmbh	Wasserlösliche Meloxicam Granulate
EP1479381A1 (en) *	2003-05-19	2004-11-24	Euro-Celtique S.A.	Pharmaceutical dosage form comprising a solid solution
EP1604666A1 (en)	2004-06-08	2005-12-14	Euro-Celtique S.A.	Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
US20070224281A1 (en) *	2004-07-22	2007-09-27	Amorepacific Corporation	Sustained-Release Preparations Containing Topiramate and the Producing Method Thereof
EP1702558A1 (en)	2005-02-28	2006-09-20	Euro-Celtique S.A.	Method and device for the assessment of bowel function
US20070048373A1 (en) *	2005-08-30	2007-03-01	Cima Labs Inc.	Dried milled granulate and methods
EP2168945A1 (en) *	2008-09-26	2010-03-31	Hexal Ag	Crystalline forms of Tilidine Mesylate
WO2010099508A1 (en)	2009-02-26	2010-09-02	Theraquest Biosciences, Inc.	Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
MY152279A (en)	2009-03-10	2014-09-15	Euro Celtique Sa	Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US10071089B2 (en)	2013-07-23	2018-09-11	Euro-Celtique S.A.	Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
EP3193845A1 (en)	2014-09-19	2017-07-26	The Procter and Gamble Company	Pulsed release phenylephrine dosage forms
US10278930B2 (en)	2017-03-16	2019-05-07	The Procter & Gamble Company	Method for relieving sinus congestion

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LU71847A1 (cs) *	1975-02-14	1977-01-05
CA2147759C (en) *	1992-10-26	2004-08-10	Wolfgang Herrmann	Tilidin dihydrogen orthophosphate, method of preparing it and pharmaceutical preparations containing it
US5965161A (en) *	1994-11-04	1999-10-12	Euro-Celtique, S.A.	Extruded multi-particulates
DE19710008A1 (de)	1997-03-12	1998-09-17	Basf Ag	Feste, mindestens zweiphasige Zubereitungsformen eines Opioid-Analgeticums mit verzögerter Freisetzung
AT500119A1 (de) *	1998-04-28	2005-10-15	Russinsky Ltd	Tilidinmethansulfonat, verfahren zu seiner herstellung und pharmazeutische masse hiervon

1998
- 1998-12-23 DE DE19859636A patent/DE19859636A1/de not_active Ceased
1999
- 1999-12-23 JP JP2000590610A patent/JP2002533381A/ja active Pending
- 1999-12-23 US US09/869,033 patent/US6579536B1/en not_active Expired - Fee Related
- 1999-12-23 AU AU22862/00A patent/AU770293B2/en not_active Ceased
- 1999-12-23 DE DE59907481T patent/DE59907481D1/de not_active Expired - Lifetime
- 1999-12-23 ES ES99967009T patent/ES2207334T3/es not_active Expired - Lifetime
- 1999-12-23 PT PT99967009T patent/PT1140031E/pt unknown
- 1999-12-23 HU HU0104647A patent/HUP0104647A3/hu unknown
- 1999-12-23 NZ NZ512079A patent/NZ512079A/en unknown
- 1999-12-23 AT AT99967009T patent/ATE252377T1/de active
- 1999-12-23 MX MXPA01006493A patent/MXPA01006493A/es not_active Application Discontinuation
- 1999-12-23 BR BR9916575-9A patent/BR9916575A/pt not_active IP Right Cessation
- 1999-12-23 CZ CZ20012167A patent/CZ301628B6/cs not_active IP Right Cessation
- 1999-12-23 SK SK892-2001A patent/SK284901B6/sk unknown
- 1999-12-23 EP EP99967009A patent/EP1140031B1/de not_active Expired - Lifetime
- 1999-12-23 DK DK99967009T patent/DK1140031T3/da active
- 1999-12-23 TR TR2001/01864T patent/TR200101864T2/xx unknown
- 1999-12-23 PL PL348419A patent/PL199024B1/pl not_active IP Right Cessation
- 1999-12-23 CA CA002355891A patent/CA2355891A1/en not_active Abandoned
- 1999-12-23 WO PCT/EP1999/010381 patent/WO2000038656A1/de not_active Ceased
2001
- 2001-06-20 NO NO20013060A patent/NO320022B1/no not_active IP Right Cessation
- 2001-06-20 ZA ZA200105040A patent/ZA200105040B/en unknown

Also Published As

Publication number	Publication date
CA2355891A1 (en)	2000-07-06
NZ512079A (en)	2003-08-29
DK1140031T3 (da)	2003-12-01
JP2002533381A (ja)	2002-10-08
HUP0104647A3 (en)	2003-12-29
WO2000038656A1 (de)	2000-07-06
PL199024B1 (pl)	2008-08-29
HUP0104647A2 (hu)	2002-03-28
HK1039273A1 (en)	2002-04-19
PT1140031E (pt)	2004-03-31
EP1140031A1 (de)	2001-10-10
EP1140031B1 (de)	2003-10-22
NO20013060L (no)	2001-06-20
NO20013060D0 (no)	2001-06-20
TR200101864T2 (tr)	2002-01-21
CZ20012167A3 (cs)	2001-11-14
AU2286200A (en)	2000-07-31
ES2207334T3 (es)	2004-05-16
ATE252377T1 (de)	2003-11-15
DE19859636A1 (de)	2000-06-29
CZ301628B6 (cs)	2010-05-05
PL348419A1 (en)	2002-05-20
SK284901B6 (sk)	2006-02-02
DE59907481D1 (de)	2003-11-27
AU770293B2 (en)	2004-02-19
BR9916575A (pt)	2001-09-18
ZA200105040B (en)	2002-05-22
MXPA01006493A (es)	2002-06-04
SK8922001A3 (en)	2001-12-03
US6579536B1 (en)	2003-06-17

Legal Events

Date	Code	Title	Description
2013-07-29	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
US10076516B2 (en)	2018-09-18	Methods of manufacturing oral dosage forms
NO320022B1 (no)	2005-10-10	Kontrollert frigjorende farmasoytisk preparat med tilidinmesylat som virkestoff
US5266331A (en)	1993-11-30	Controlled release oxycodone compositions
CN103002882B (zh)	2016-03-02	不含活性剂之颗粒及包含其之片剂的制备
US10179130B2 (en)	2019-01-15	Controlled release hydrocodone formulations
HK1039273B (en)	2004-03-12	Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient